Leptomeningeal Metastases Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Leptomeningeal Metastases pipeline constitutes 5+ key companies continuously working towards developing 5+ Leptomeningeal Metastases treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Leptomeningeal Metastases Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Leptomeningeal Metastases Market.

The Leptomeningeal Metastases Pipeline report provides a thorough evaluation of both the commercial and clinical aspects of pipeline products, spanning from the pre-clinical development stage to the marketed phase. It includes a comprehensive description of each drug, encompassing its mechanism of action, clinical studies, any approvals through New Drug Applications (NDAs), and various product development activities. These activities involve technological advancements, collaborations, mergers and acquisitions, funding details, designations, and other pertinent information related to the product.

Some of the key takeaways from the Leptomeningeal Metastases Pipeline Report: https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Leptomeningeal Metastases treatment therapies with a considerable amount of success over the years.
• Leptomeningeal Metastases companies working in the treatment market are NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem, and others, are developing therapies for the Leptomeningeal Metastases treatment
• Emerging Leptomeningeal Metastases therapies in the different phases of clinical trials are- Rhenium-186, AZD1390, TY-9591, ANG1005, and others are expected to have a significant impact on the Leptomeningeal Metastases market in the coming years.
• In May 2025, A single dose of rhenium (Re186) obisbemeda (Reyobiq; 186RNL) was well tolerated and showed initial clinical benefit in patients with leptomeningeal metastases, based on findings from the Phase 1 dose-escalation ReSPECT-LM trial (NCT05034497).
• In April 2025, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers using advanced platform technologies, has announced the online release of new data on its lead compound, REYOBIQTM (rhenium Re186 obisbemeda). This data will be featured in an abstract for both an oral presentation and a poster at the Nuclear Medicine and Neurooncology conference.
• In March 2025, The FDA has awarded orphan drug designation to the investigational radiotherapeutic rhenium (186Re) obisbemeda as a potential treatment for leptomeningeal metastases in patients with lung cancer. This therapy is designed to administer highly targeted, high-dose radiation directly to central nervous system (CNS) tumors, aiming to enhance both safety and efficacy through a more potent and localized radiation dose compared to existing treatments.

Leptomeningeal Metastases Overview
Leptomeningeal carcinomatosis (LC), commonly referred to as "leptomeningeal metastases" or "carcinomatosis meningitis," is a condition in which the brain's pia and arachnoid mater, as well as the subarachnoid space in between, are affected by cancer. It was initially described in the late 19th century, and numerous research have been done since on the topic.

Get a Free Sample PDF Report to know more about Leptomeningeal Metastases Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Leptomeningeal Metastases Drugs Under Different Phases of Clinical Development Include:
• AZD1390: AstraZeneca
• TY-9591: TYK Medicine
• Rhenium-186: NanoLiposome Plus Therapeutics
• ANG1005: Angiochem

Leptomeningeal Metastases Pipeline Therapeutics Assessment
• Leptomeningeal Metastases Assessment by Product Type
• Leptomeningeal Metastases By Stage and Product Type
• Leptomeningeal Metastases Assessment by Route of Administration
• Leptomeningeal Metastases By Stage and Route of Administration
• Leptomeningeal Metastases Assessment by Molecule Type
• Leptomeningeal Metastases by Stage and Molecule Type

DelveInsight's Leptomeningeal Metastases Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Leptomeningeal Metastases product details are provided in the report. Download the Leptomeningeal Metastases pipeline report to learn more about the emerging Leptomeningeal Metastases therapies
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Leptomeningeal Metastases Therapeutics Market include:
Key companies developing therapies for Leptomeningeal Metastases are - AstraZeneca, Angiochem., Plus Therapeutics, Y-mAbs Therapeutics, and others.

Leptomeningeal Metastases Pipeline Analysis:
The Leptomeningeal Metastases pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Leptomeningeal Metastases with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Leptomeningeal Metastases Treatment.
• Leptomeningeal Metastases key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Leptomeningeal Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Leptomeningeal Metastases market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Leptomeningeal Metastases drugs and therapies
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Leptomeningeal Metastases Pipeline Market Drivers
• Increasing Prevalence of Leptomeningeal Metastasess, increase in research and developmental activities are some of the important factors that are fueling the Leptomeningeal Metastases Market.

Leptomeningeal Metastases Pipeline Market Barriers
• However, high-cost associated with the disease, side-effects associated with the treatment and other factors are creating obstacles in the Leptomeningeal Metastases Market growth.

Scope of Leptomeningeal Metastases Pipeline Drug Insight
• Coverage: Global
• Key Leptomeningeal Metastases Companies: NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem, and others
• Key Leptomeningeal Metastases Therapies: Rhenium-186, AZD1390, TY-9591, ANG1005, and others
• Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies
• Leptomeningeal Metastases Market Dynamics: Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers

Request for Sample PDF Report for Leptomeningeal Metastases Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Leptomeningeal Metastases Report Introduction
2. Leptomeningeal Metastases Executive Summary
3. Leptomeningeal Metastases Overview
4. Leptomeningeal Metastases- Analytical Perspective In-depth Commercial Assessment
5. Leptomeningeal Metastases Pipeline Therapeutics
6. Leptomeningeal Metastases Late Stage Products (Phase II/III)
7. Leptomeningeal Metastases Mid Stage Products (Phase II)
8. Leptomeningeal Metastases Early Stage Products (Phase I)
9. Leptomeningeal Metastases Preclinical Stage Products
10. Leptomeningeal Metastases Therapeutics Assessment
11. Leptomeningeal Metastases Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Leptomeningeal Metastases Key Companies
14. Leptomeningeal Metastases Key Products
15. Leptomeningeal Metastases Unmet Needs
16 . Leptomeningeal Metastases Market Drivers and Barriers
17. Leptomeningeal Metastases Future Perspectives and Conclusion
18. Leptomeningeal Metastases Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Leptomeningeal Metastases Market https://www.delveinsight.com/report-store/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Leptomeningeal Metastases-Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Leptomeningeal Metastases Epidemiology https://www.delveinsight.com/report-store/leptomeningeal-metastases-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Leptomeningeal Metastases Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.